NCT05949593Phase 3Active not recruiting

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy

Study sponsor: Belite Bio, Inc · BLTE

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-06-30Estimated
Enrollment · participants429Estimated
Source updated2026-01-07Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 2 fields changed

Primary completion date changed

Before: 31 Aug 2027. After: 30 Jun 2027.

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source